CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Gastric electrical stimulation (implantable gastric neurostimulator) coverage criteria

Defines coverage and coding stance for implantation and related services for implantable gastric electrical stimulation devices for gastroparesis and obesity for Blue Cross Blue Shield - Rhode Island members.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyGastric electrical stimulation (implantable gastric neurostimulator) coverage criteria

Policy CodePolicy N/A

Change TypeNo material clinical or coverage changes

Effective DateJan 10, 2021

Next Review DateN/A

Key ActionVerify member benefits and coverage with the benefit booklet or provider call center before submitting claims.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not coveredImplantation (Medicare Advantage)

Not medically necessaryImplantation (Commercial)

5RCTs in meta-analysis

43647, 43881, 95980-82Explicit CPT codes listed

SHAPEKey obesity RCT

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria — Gastric Electrical Stimulation

inv-01: Not Covered / Not Medically Necessary

Covered when ALL of the following are met:

Overall coverage stance: Implantation of a gastric electrical stimulation device for any indication is not covered for Medicare Advantage plans and is considered not medically necessary for Commercial products because evidence is insufficient to determine effects on health outcomes.

Includes use for gastroparesis and obesity; Enterra system is FDA HDE but evidence remains insufficient per policy.

inv-02: Evidence considerations

Summary of clinical evidence considered in reaching the coverage stance:

Gastroparesis evidence: Randomized controlled trials and a 2017 meta-analysis of five crossover RCTs did not demonstrate a significant benefit of gastric electrical stimulation (GES) on severity of gastroparesis symptoms; symptom improvements occurred regardless of device activation, suggesting a placebo effect. The evidence is insufficient to determine effects on health outcomes.

Five crossover RCTs included in the 2017 meta-analysis.

Obesity evidence: For obesity, the SHAPE randomized controlled trial did not show a significant improvement in weight loss with GES versus sham stimulation. No GES devices are FDA-approved for treatment of obesity. The evidence is insufficient to determine effects on health outcomes.

Transcend device available in Europe; no FDA approval for obesity indications.

This policy addresses the insertion or implantation of an implantable gastric electrical stimulation device (also referred to as a gastric pacemaker) and documents that such implantation is not considered a covered, medically necessary service under this policy. The policy applies to use of the device for gastroparesis (including diabetic, idiopathic, and post‑surgical etiologies) and for investigational indications such as obesity. For guidance on removal of a device that is non‑covered under this policy, refer to the separate policy titled Removal of Non‑Covered Implantable Devices.

For Commercial Products, implantation of a gastric electrical stimulation device for any indication is considered not medically necessary because the available evidence is insufficient to determine effects on health outcomes. For Medicare Advantage Plans, implantation of a gastric electrical stimulation device for any indication is not covered. The policy lists specific CPT codes that will be denied or are not medically necessary when billed for implantation and related electronic analysis (see coding section for codes).

Evidence supporting these stances includes randomized controlled trials and systematic reviews for gastroparesis and obesity. A 2017 meta‑analysis of five crossover RCTs for gastroparesis did not find a significant benefit of gastric electrical stimulation on symptom severity, with symptom improvement observed regardless of whether the device was active, suggesting a placebo effect. The SHAPE trial for obesity did not show significant weight loss benefit compared with sham stimulation. Taken together, the evidence is insufficient to establish clinical benefit for either gastroparesis or obesity.

Coding — Affected Procedure and Diagnosis Codes

Not Covered / Not Medically Necessary CPT Codes (GES)CPTNot Covered

43647	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum
43881	Implantation or replacement of gastric neurostimulator electrodes, antrum, open
95980	Electronic analysis of implanted neurostimulator pulse generator system (e.g., rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements), gastric neurostimulator pulse generator/transmitter; intraoperative, with programming
95981	Electronic analysis of implanted neurostimulator pulse generator system (e.g., rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements), gastric neurostimulator pulse generator/transmitter; subsequent, without reprogramming
95982	Electronic analysis of implanted neurostimulator pulse generator system (e.g., rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements), gastric neurostimulator pulse generator/transmitter; subsequent, with reprogramming

Not Covered / Not Medically Necessary Codes (Obesity-related GES reporting)mixedNot Covered

43659	Unlisted laparoscopy procedure, stomach (used for laparoscopic procedures related to GES for morbid obesity)
43999	Unlisted procedure, stomach (used for laparotomy procedures related to GES for morbid obesity)
64590	Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling (not covered when used for GES with listed diagnoses)

Not Covered / Not Medically Necessary Codes (Obesity-related GES reporting)mixedNot Covered

43659	Unlisted laparoscopy procedure, stomach (used for laparoscopic procedures related to GES for morbid obesity)
43999	Unlisted procedure, stomach (used for laparotomy procedures related to GES for morbid obesity)
64590	Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling (not covered when used for GES with listed diagnoses)

ICD-10 codes referencedICD-10

E08.43	Diabetes mellitus due to underlying condition with gastroparesis
E09.43	Drug or chemical induced diabetes mellitus with gastroparesis
E10.43	Type 1 diabetes mellitus with gastroparesis
E11.43	Type 2 diabetes mellitus with gastroparesis
E13.43	Other specified diabetes mellitus with gastroparesis
E66.01-E66.9	Obesity codes range
K31.89	Other diseases of stomach and duodenum (used in policy context)

Provider Actions and Billing Guidance

Prior Authorization

Prior Authorization / Benefit Verification

Prior authorization is not applicable for this policy. However, benefits and coverage can vary by member and contract; providers should always verify member-specific benefits prior to scheduling services.

Check the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for plan-specific coverage details.
Contact the payer's provider call center for member-specific benefit verification.

Denial Risk

Denial Triggers for Implantation and Related Programming/Analysis

Providers should note that implantation and related programming/analysis services for gastric neurostimulators are considered not covered or not medically necessary under this policy. Claims for these services may be denied; submit documentation only when appealing a denial with clear clinical justification.

Denied/Not covered (Medicare Advantage): 43647, 43881, 95980, 95981, 95982

Background — Clinical Context

Gastroparesis is a chronic disorder of gastric motility characterized by delayed gastric emptying that leads to symptoms including persistent nausea, vomiting, bloating, early satiety, and potential nutritional compromise. It most commonly occurs in patients with diabetes but can also be idiopathic or occur after surgery.

Gastric electrical stimulation (GES) involves an implanted pulse generator with intramuscular stomach leads (commonly referred to as a gastric pacemaker) that delivers programmed electrical pulses to the stomach. GES has been investigated primarily for chronic, drug‑refractory nausea and vomiting due to gastroparesis and, separately, has been studied as a potential therapy for obesity, though no FDA‑approved devices exist for obesity treatment.

Definitions and Device Terms

Gastric electrical stimulation (GES) / Enterra Therapy System — device description and implantation method

Device componentsImplantable pulse generator, two unipolar intramuscular stomach leads, external stimulator programmer, and memory cartridge (Enterra Therapy System)

Implantation methodIntramuscular stomach leads are implanted laparoscopically or via open laparotomy and connected to a pulse generator placed in a subcutaneous pocket

Stimulation parametersProgrammer typically set to an 'on' time of 0.1 seconds alternating with an 'off' time of 5.0 seconds

Regulatory status (Enterra)Enterra Therapy System cleared by FDA through the humanitarian device exemption process (HDE) for gastroparesis

Shared technologyExcept for the intramuscular leads, components are similar to other implantable neurologic stimulators (e.g., spinal cord or sacral nerve stimulators)